Skip to main content

Prophylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative Morbidity

Abstract

Background

Prophylactic cholecystectomy at time of surgery for small bowel neuroendocrine tumor (SBNET) has been advocated, as these patients often go on to require somatostatin analogue therapy, which is known to increase risk of cholestasis and associated complications. Little is known regarding patterns of adoption of this practice or its associated morbidity.

Methods

The American College of Surgeons National Surgical Quality Improvement Program database (2008–2014) was queried to identify patients who underwent SBNET resection. The risk differences of morbidity and mortality associated with performance of concurrent cholecystectomy were determined with multivariable adjustment for confounders.

Results

Among 1300 patients who underwent SBNET resection, 144 (11.1%) underwent concurrent cholecystectomy. Median age of patients undergoing cholecystectomy was 62 years [interquartile range (IQR) 52–69 years], and 75 were male. They more commonly had disseminated cancer (36.1 vs. 11.6%, p < 0.001) or SBNET located in duodenum (10.4 vs. 4.9%, p = 0.045) without difference in other baseline characteristics. Operative time was significantly longer in the cholecystectomy group (median 172 vs. 123 min, p < 0.001). Rate of postoperative morbidity was not significantly different between cholecystectomy and no-cholecystectomy groups (11.8 vs. 11.1%, p = 0.79). After adjustment for confounding, the risk difference of morbidity attributable to cholecystectomy was + 0.4% [95% confidence interval (CI) − 4.9 to + 5.6%]. Mortality within 30 days was not significantly different between cholecystectomy and no-cholecystectomy groups (1.4 vs. 0.6%, p = 0.29).

Conclusions

Concurrent cholecystectomy at time of resection of SBNET is not associated with higher morbidity or mortality yet is performed in a minority of patients. Prospective study can identify which patients may derive benefit from this approach.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Doherty G. Surgical treatment of neuroendocrine tumors (including carcinoid). Curr Opin Endocrinol Diabetes Obes. 2013;20(1):32–6.

    Article  PubMed  Google Scholar 

  2. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014;21(1):240–7.

    Article  PubMed  Google Scholar 

  3. Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21(5):534–45.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008;31(8):704–10.

    CAS  Article  PubMed  Google Scholar 

  5. Daughaday WH. Octreotide is effective in acromegaly but often results in cholelithiasis. Ann Intern Med. 1990;112(3):159–60.

    CAS  Article  PubMed  Google Scholar 

  6. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients–a clinical research center study. J Clin Endocrinol Metab. 1995;80(9):2768–75.

    CAS  PubMed  Google Scholar 

  7. Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab. 1990;71(6):1658–62.

    CAS  Article  PubMed  Google Scholar 

  8. Redfern JS, Fortuner WJ, 2nd. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol. 1995;90(7):1042–52.

    CAS  PubMed  Google Scholar 

  9. Norlen O, Hessman O, Stalberg P, Akerstrom G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg. 2010;34(6):1361–7.

    Article  PubMed  Google Scholar 

  10. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 15 1997;79(4):830–4.

    CAS  Article  PubMed  Google Scholar 

  11. Norton E, Miller M, Kleinman L. Computing adjusted risk ratios and risk differences in Stata. The Stata Journal. 2013;13(3):492–509.

    Google Scholar 

  12. Stata Statistical Software: Release 14 [computer program]. College Station, TX: StataCorp, LP; 2015.

    Google Scholar 

  13. Reissman P, Shmailov S, Grozinsky-Glasberg S, Gross DJ. Laparoscopic resection of primary midgut carcinoid tumors. Surg Endosc. 2013;27(10):3678–82.

    Article  PubMed  Google Scholar 

  14. Harris H. Biliary system. In: Norton J, Barie P, eds. Surgery: basic science and clinical evidence, 2nd ed. New York: Springer; 2008.

    Google Scholar 

  15. Neylan CJ, Damrauer SM, Kelz RR, et al. The role of body mass index class in cholecystectomy after acute cholecystitis: An American College of Surgeons National Surgical Quality Improvement Program analysis. Surgery. 2016;160(3):699–707.

    Article  PubMed  Google Scholar 

  16. Amstutz S, Michel JM, Kopp S, Egger B. Potential benefits of prophylactic cholecystectomy in patients undergoing bariatric bypass surgery. Obes Surg. 2015;25(11):2054–60.

    Article  PubMed  Google Scholar 

  17. Coskun H, Hasbahceci M, Bozkurt S, et al. Is concomitant cholecystectomy with laparoscopic sleeve gastrectomy safe? Turk J Gastroenterol. 2014;25(6):624–7.

    Article  PubMed  Google Scholar 

  18. Dakour-Aridi HN, El-Rayess HM, Abou-Abbass H, Abu-Gheida I, Habib RH, Safadi BY. Safety of concomitant cholecystectomy at the time of laparoscopic sleeve gastrectomy: analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Surg Obes Relat Dis. 2016;13(6):934–41.

    Article  PubMed  Google Scholar 

  19. Nougou A, Suter M. Almost routine prophylactic cholecystectomy during laparoscopic gastric bypass is safe. Obes Surg. 2008;18(5):535–9.

    CAS  Article  PubMed  Google Scholar 

  20. Tarantino I, Warschkow R, Steffen T, Bisang P, Schultes B, Thurnheer M. Is routine cholecystectomy justified in severely obese patients undergoing a laparoscopic Roux-en-Y gastric bypass procedure? A comparative cohort study. Obes Surg. 2011;21(12):1870–8.

    Article  PubMed  Google Scholar 

  21. Kaibori M, Kubo S, Nagano H, et al. Higher complication rate in hepatocellular carcinoma patients undergoing prophylactic cholecystectomy with curative hepatic resection. Hepatogastroenterology. 2014;61(135):2028–34.

    PubMed  Google Scholar 

  22. Orr NT, Davenport DL, Roth JS. Outcomes of simultaneous laparoscopic cholecystectomy and ventral hernia repair compared to that of laparoscopic cholecystectomy alone. Surg Endosc. 2013;27(1):67–73.

    Article  PubMed  Google Scholar 

Download references

Funding

None.

Disclosure

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew J. Sinnamon MD.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sinnamon, A.J., Neuwirth, M.G., Vining, C.C. et al. Prophylactic Cholecystectomy at Time of Surgery for Small Bowel Neuroendocrine Tumor Does Not Increase Postoperative Morbidity. Ann Surg Oncol 25, 239–245 (2018). https://doi.org/10.1245/s10434-017-6093-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6093-y

Keywords

  • Small Bowel Neuroendocrine Tumors (SBNET)
  • Prophylactic Cholecystectomy
  • Concurrent Cholecystectomy
  • Somatostatin Analog Therapy
  • National Surgical Quality Improvement Program